This site has been optimized to work with modern browsers and does not fully support your version of Internet Explorer.

Targeting type 1FN in immune-mediated inflammatory disease



Speakers: Dr Hussein Al-Mossawi (Global Clinical Head for Anifrolumab, Late Respiratory and Immunology)

Company: AstraZeneca

Building on decades of research, AstraZeneca is starting to unravel complex inflammatory cell signalling pathways and uncover key drivers that cause an imbalance in immune-mediated diseases.

This seminar is part of the University of Oxford Medical Sciences Division’s, Industry Insights Seminar Series.

Further information and booking details

Event Types: Partner event